Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patients

Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patients - Kansai - Collaborative Anti-atherothrombotic Medicine study group

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028634

Enrollment

100

Registered

2017-09-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

tofogliflozin anagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. under treatment by dialy DPP-4 blocker 2. 7.5% < HbA1c < 9.0% 3. BMI > 18.0 kg/m2 4. 20 years < age < 95 years 5. written informed concent

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes or secondary diabetes 2. contraindication for medicine 3. allergy 4. eGFR < 30mL/min/1.73m2 5. AST or ALT > 120IU/L 6. history of appoplexy 7. pregnancy or lactationperiod 8. urinary infection, social disease 9. malignancy 10. inappropriate patients

Design outcomes

Primary

Measure	Time frame
Comparison of HbA1c during 24 weeks from baseline	—

Countries

Japan

Contacts

Public ContactShosaku Nomura

Kansai Medical University First Department of Internal Medicine

nomurash@hirakata.kmu.ac.jp0728042754

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026